Compare Lockheed Martin Corporation (LMT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Lockheed Martin Corporation trades at $525.82 (market cap $116.32B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Lockheed Martin Corporation is far larger — about 15.5× Spyre Therapeutics Inc. Common Stock's market cap, and Lockheed Martin Corporation pays a 2.86% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LMT | SYRE | |
|---|---|---|
Market Cap | $116.32B | $7.52B |
Volume | 860,316 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $676.70 | $108.92 |
52-Week Low | $439.19 | $22.18 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $133.07B | $6.52B |
Dividend Yield | 2.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $522.23, up 2.02% today, with a bearish technical signal and neutral oscillators. The company reported revenue of $75.05 billion in 2025, with net income of $5.02 billion, though recent quarters show mixed earnings results. Analysts maintain a strong buy consensus with a $625.64 price target. Recent news highlights ongoing dividend increases, AI integration efforts, and new defense contracts, supporting long-term growth prospects amid stable cash flows.
The outlook for LMT is positive, driven by robust defense spending and strategic innovations, but risks include reliance on government contracts and fixed-price contract volatility. The stock offers value with a P/E of 18.58 and a dividend yield supported by 23 years of increases, though technical indicators suggest near-term caution.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
